ReviewEpilepsy research2009
Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.
Review in Epilepsy research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 91 citations in OpenAlex.
- Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.Molecular neurobiology · 2026Review
- Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury.CNS neuroscience & therapeutics · 2026Review
- Therapeutic Potential Target of Adenosine for Epilepsy: Focusing on Its Interaction with the Molecular Epileptogenic Network.Biomolecules · 2026Review
- Calponin-3 is associated with epilepsy through the regulation of astrocyte activity.Brain pathology (Zurich, Switzerland) · 2026Article
- Adenosine Kinase: An Epigenetic Modulator and Drug Target.Journal of inherited metabolic disease · 2025Review
- The Good, the Bad, and the Deadly: Adenosinergic Mechanisms Underlying Sudden Unexpected Death in Epilepsy.Frontiers in neuroscience · 2021Review
- The role of adenosine in epilepsy.Brain research bulletin · 2019Review
- Astroglial role in the pathophysiology of statusOncotarget · 2018Review
- Adenosinergic signaling in epilepsy.Neuropharmacology · 2016Review
- Inhibition of Adenosine Kinase Attenuates Acute Lung Injury.Critical care medicine · 2016Article
- The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and Glycine.Frontiers in molecular neuroscience · 2016Review
- Adenosine deaminase and adenosine kinase expression in human glioma and their correlation with glioma‑associated epilepsy.Molecular medicine reports · 2015Article
- Purine receptors are required for DHA-mediated neuroprotection against oxygen and glucose deprivation in hippocampal slices.Purinergic signalling · 2015Article
- Adenosine-associated delivery systems.Journal of drug targeting · 2015Review
- Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice.Journal of neurosurgery · 2014Article
- Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase.Cerebral cortex (New York, N.Y. : 1991) · 2014Article
- Glial adenosine kinase--a neuropathological marker of the epileptic brain.Neurochemistry international · 2013Review
- Sudden unexpected death in Dravet syndrome: respiratory and other physiological dysfunctions.Respiratory physiology & neurobiology · 2013Review
- Role of adenosine in status epilepticus: a potential new target?Epilepsia · 2013Review
- Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.The Journal of clinical investigation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Deficiencies in the brain's own adenosine-based seizure control system contribute to seizure generation. Consequently, reconstitution of adenosinergic neuromodulation constitutes a rational approach for seizure control. This review will critically discuss focal adenosine augmentation strategies and their potential for antiepileptic and disease modifying therapy. Due to systemic side effects of adenosine focal adenosine augmentation--ideally targeted to an epileptic focus--becomes a therapeutic necessity. This has experimentally been achieved in kindled seizure models as well as in post-status epilepticus models of spontaneous recurrent seizures using three different therapeutic strategies that will be discussed here: (i) polymer-based brain implants that were loaded with adenosine; (ii) brain implants comprised of cells engineered to release adenosine and embedded in a cell-encapsulation device; (iii) direct transplantation of stem cells engineered to release adenosine. To meet the therapeutic goal of focal adenosine augmentation, genetic disruption of the adenosine metabolizing enzyme adenosine kinase (ADK) in rodent and human cells was used as a molecular strategy to induce adenosine release from cellular brain implants, which demonstrated antiepileptic and neuroprotective properties. New developments and therapeutic challenges in using AATs for epilepsy therapy will critically be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.